Product Search

#11081 Anti-Human VEGF (2E1) Mouse IgG MoAb

Intended Use:
Research reagents
Application:
WB, IHC
Package Size1:
500 μg
Package Size2:
50 μg
Note on Application Abbreviations
WB:Western Blotting
IHC:Immunohistochemistry

※ The product indicated as "Research reagents" in the column Intended Use cannot be used
  for diagnostic nor any medical purpose.
※ The datasheet listed on this page is sample only. Please refer to the datasheet
  enclosed in the product purchased before use.

Product Overview

Product Overview

Product Code 11081
Product Name Anti-Human VEGF (2E1) Mouse IgG MoAb
Intended Use Research reagents
Application WB, IHC
Species Human
Immunizing antigen Recombinant Human VEGF (E. coli)
Source Mouse-Mouse hybridoma (X63 - Ag 8.653 × BALB/c mouse spleen)
Clone Name 2E1
Subclass IgG2b
Purification Method Affinity purified with protein A
Package Form Lyophilized product from PBS containing 1 % BSA and 0.05 % NaN3
Storage Condition 2 - 8℃
Poisonous and Deleterious Substances Applicable
Cartagena Not Applicable
Package Size 1 500 μg
Package Size 2 50 μg
Remarks1 The commercial use of products without our permission is prohibited. Please make sure to contact us and obtain permission.

Product Description

Product Description

Vascular Endothelial Cell Growth Factor (VEGF) is a homodimeric protein initially purified from media conditioned by normal bovine pituitary folliculo-stellate cells and secreted by a variety of vascularized tissues. It was subsequently found to be identical to a vascular permeability factor (VPF), which was previously identified in media conditioned by tumor cell lines based upon its ability to increase the permeability of capillary blood vessels. The reported activities of VEGF include stimulation of endothelial cell growth, angiogenesis and capillary permeability. Human VEGF is a 38.2kDa homodimeric protein consisting of two 165 amino acid polypeptide chains. VEGF is expressed in many human tumor cells, including human adenocarcinoma, human pancreatic carcinoma, human hepatocellular carcinoma, renal cell carcinoma, fibrosarcoma, HL60 promyelocytic leukemia, GS-9L glioma and U937 lymphoma cells. In normal tissues, VEGF expression has been observed in activated macrophages, keratinocytes, hepatocytes, smooth muscle cells Leydig cells, embryonic fibroblasts and bronchial and choroids plexus epithelium, renal glomerular visceral epithelium and mesangial cells.